GSK plc (GSK.L) Stock Analysis
$GSK.L · Healthcare · Drug Manufacturers - General · LSE
GSK (GSK.L), a Drug Manufacturers - General company, is listed on LSE, has a market capitalization of about $74.63B and trades at 14.8x trailing earnings.
Price
$1862.50
Market cap
$74.63B
P/E ratio
14.8x
Dividend yield
3.65%
About GSK plc
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional sup
How StockWorthy values GSK.L
StockWorthy forecasts GSK plc's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from GSK.L's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See GSK.L's Fair Value
Create a free account to view GSK plc's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.